{"id":"NCT00762463","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Study Of Celecoxib Or Diclofenac For Efficacy and Safety In Chinese Patients With Ankylosing Spondylitis","officialTitle":"A 6-Week, Randomized, Double-Blind, Parallel-Group Study To Evaluate The Symptomatic Effects And Safety Of Celecoxib 200mg QD Compared To Diclofenac 75mg SR QD In Chinese Patients With Ankylosing Spondylitis, With 6-Week Extension Phase Treatment On Celecoxib 400 Mg QD Or Maintaining Double-Blind Phase Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2010-06","completion":"2010-08","firstPosted":"2008-09-30","resultsPosted":"2011-08-23","lastUpdate":"2021-02-02"},"enrollment":240,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Ankylosing Spondylitis"],"interventions":[{"type":"DRUG","name":"Celecoxib","otherNames":[]},{"type":"DRUG","name":"Diclofenac SR","otherNames":[]}],"arms":[{"label":"Celecoxib 200 mg QD","type":"EXPERIMENTAL"},{"label":"Diclofenac SR 75 mg QD","type":"ACTIVE_COMPARATOR"}],"summary":"This is a local, multicenter, randomized, active comparator, double-blind, parallel group study with extension will be conducted to evaluate the efficacy and safety of celecoxib versus diclofenac SR in the treatment of Chinese patients with Ankylosing Spondylitis (AS).","primaryOutcome":{"measure":"Change From Baseline in Participant's Assessment of Global Pain Intensity at Week 6","timeFrame":"Baseline, Week 6","effectByArm":[{"arm":"Celecoxib 200 mg","deltaMin":-23.8,"sd":1.98},{"arm":"Diclofenac SR 75 mg","deltaMin":-27.1,"sd":2.02}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0085"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":5,"countries":["China"]},"refs":{"pmids":["25516774"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3191348&StudyName=Study%20Of%20Celecoxib%20Or%20Diclofenac%20For%20Efficacy%20and%20Safety%20In%20Chinese%20Patients%20With%20Ankylosing%20Spondylitis"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":120},"commonTop":["Upper respiratory tract infection","Alanine aminotransferase increased","Hepatic function abnormal","Abdominal pain upper","Transaminases increased"]}}